Vensica Medical Revenue and Competitors
Employee Data
- Vensica Medical has 10 Employees.
- Vensica Medical grew their employee count by 25% last year.
Vensica Medical's People
Name | Title | Email/Phone |
---|
Vensica Medical Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 81 | 8% | N/A | N/A |
#2 | N/A | 72 | 26% | N/A | N/A |
#3 | N/A | 93 | 27% | N/A | N/A |
#4 | $35M | 76 | 7% | N/A | N/A |
#5 | N/A | 60 | 22% | N/A | N/A |
#6 | N/A | 179 | -6% | N/A | N/A |
#7 | N/A | 52 | 37% | N/A | N/A |
#8 | N/A | 1085 | 12% | N/A | N/A |
#9 | N/A | 35 | 9% | N/A | N/A |
#10 | $3.5M | 44 | 13% | N/A | N/A |
What Is Vensica Medical?
Vensica Medical is pioneering a new era in urology therapeutics with Vibe®, a patented ultrasound-driven drug delivery platform designed to transform how medications are delivered to the bladder. \n\nOur lead therapeutic, ViXe, combines FDA-approved Xeomin® (Botulinum Toxin A) with the Vibe catheter, a breakthrough needle-free ultrasound device.\n\nVibe enables the delivery of drugs directly into the bladder wall, offering precise, controlled, and localized treatments. This minimally invasive approach aims to improve outcomes, reduce side effects, and enhance patient comfort.\n\nBy enabling the delivery of various bladder-targeted therapies, Vibe technology unlocks new opportunities for treating unmet medical needs. Therapeutics are in development for overactive bladder (OAB), bladder cancer, neurogenic bladder, and interstitial cystitis.\n\nJoin us in shaping the future of urology therapeutics >> https://vensica.com/
keywords:N/AN/A
Total Funding
10
Number of Employees
N/A
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1M | 11 | N/A | N/A |
#2 | $1.8M | 12 | 0% | N/A |
#3 | $4M | 16 | 7% | N/A |
#4 | $3.3M | 17 | 6% | N/A |
#5 | $2.1M | 21 | -9% | N/A |